What is the infection rate and management of Nipah virus infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nipah Virus Infection Rate and Management

Infection Rate and Transmission Dynamics

The secondary attack rate for Nipah virus is approximately 50% among household contacts, making it significantly more contagious than many other infectious diseases, with an overall case fatality rate ranging from 40% to 75%. 1, 2, 3

Primary Transmission Patterns

  • Primary infection occurs in approximately 50% of cases through consumption of raw date palm sap or fermented date palm sap (tari) contaminated by fruit bats, which serve as the natural reservoir 4

  • Person-to-person transmission accounts for 29% of infections, predominantly through close contact with infected individuals or their bodily fluids 4

  • The secondary attack rate of 50% among household contacts is substantially higher than meningococcal disease (4 per 1,000 household contacts), indicating extremely high transmissibility in close-contact settings 1

Epidemiological Burden

  • From 2006 to 2021 in Bangladesh, 322 Nipah infections were identified through systematic surveillance, with 75% being laboratory-confirmed cases 4

  • The overall case fatality rate in Bangladesh has remained consistently at 71%, though global rates vary from 40% to 100% depending on healthcare availability, patient condition, and viral strain virulence 2, 4, 5

  • Clinical manifestations include fever, vomiting, headache, fatigue, and increased salivation as the most common symptoms, progressing to severe respiratory illness and fatal encephalitis 2, 4

Management Approach

There are currently no licensed treatments or vaccines for Nipah virus infection; management is limited to aggressive supportive care with early intubation and intensive monitoring. 6, 7, 5

Respiratory Management

  • Early intubation with invasive mechanical ventilation is mandatory for patients with severe hypoxemia rather than attempting non-invasive ventilation, as delays in intubation worsen outcomes and put healthcare workers at unnecessary risk during emergency intubation 6

  • If non-invasive ventilation or high-flow nasal oxygen is attempted in carefully selected patients with mild respiratory distress, it must be done in an ICU setting with strict airborne precautions, proper interface fitting, and a low threshold for proceeding to intubation if no improvement occurs 6

  • Continuous monitoring with preparedness for urgent intubation is essential, as treatment failure rates with non-invasive ventilation are high in severe viral infections 6

Critical Care Monitoring

  • ICU-level monitoring is mandatory with continuous assessment of vital signs, oxygen saturation, neurological status, water-electrolyte balance, acid-base balance, and organ function 6

  • Monitor for complications including acute respiratory distress syndrome, septic shock, stress ulcers, and deep vein thrombosis 6

  • Continuous EEG monitoring is required to detect subclinical seizure activity, particularly when myoclonic jerks with characteristic 1:1 relationship to EEG periodic complexes are present, indicating severe CNS involvement 6

Neurological Management

  • Aggressive anticonvulsant therapy is required for myoclonic seizures and status epilepticus, with continuous EEG monitoring 6

  • Myoclonic jerks, dystonia, areflexia, and hypotonia are poor prognostic neurological signs requiring intensive management 6

Antiviral Considerations

  • Ribavirin can be considered for Nipah virus encephalitis, though evidence for efficacy is limited (C-III recommendation from the Infectious Diseases Society of America) 6

  • No specific therapeutic drugs are currently available, and management remains primarily supportive 3, 7

Nutritional Support

  • Provide high-protein, high-vitamin, carbohydrate-containing diets for patients who can tolerate oral intake 6

  • For critically ill patients, dynamically assess nutritional risks and provide enteral nutrition as soon as possible; if not feasible, initiate parenteral nutrition promptly to meet energy requirements 6

Infection Control Measures

  • Healthcare workers must use airborne precautions with N-95 respirators, gowns, aprons, and face shields when caring for suspected or confirmed cases, as person-to-person transmission occurs in approximately 50% of cases 6

  • Strict isolation protocols are essential given the high secondary attack rate among close contacts 1

Diagnostic Approach

  • Herpes simplex PCR should be performed on all CSF specimens to rule out treatable causes of encephalitis 6

  • Laboratory confirmation through serology and molecular detection is essential for definitive diagnosis 4

Critical Pitfalls to Avoid

  • Do not delay intubation by attempting prolonged trials of non-invasive ventilation or high-flow nasal oxygen—this increases mortality and puts staff at risk during emergency intubation 6

  • Do not discharge patients without comprehensive follow-up plans, as neurological sequelae may emerge later 6

  • Do not underestimate the transmission risk—the 50% secondary attack rate among household contacts requires aggressive isolation and contact tracing 1

References

Guideline

Nipah Virus Transmission and Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Progress in prevention and control of Nipah virus disease].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2022

Guideline

Nipah Virus Infection Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Nipah Virus: An Updated Review and Emerging Challenges.

Infectious disorders drug targets, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.